Slide 1: Atomo Diagnostics FY24 Results Presentation
For personal use only ATOMO DIAGNOSTCS FY24 RESULTS PRESENTATION 29 AUGUST 2024
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on omissions from, any other written or oral communications transmitted or otherwise made information available as at the date of this presentation. The information in this available to the recipient in conne
Slide 3: Why Atomo?
WHY ATOMO? Atomo is a highly differentiated commercial-stage rapid test business, with sales generated through a number of global supply channels Technologically proven and commercialised platforms addressing an expanding rapid-testing market driven by public health and consumer For personal use onl
Slide 4: Favorable Market Landscape
FAVORABLE MARKET LANDSCAPE Pathology companies now Expansion of decentralised and at-home diagnostics as the market demands reduced actively seeking access to at home testing business models [6] burden on healthcare infrastructure and improved convenience for patients and consumers Global point-of-c
Slide 5: Transformative Innovation
TRANSFORMATIVE INNOVATION For personal use only Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices Complex Accurate • Multiple components • Easy to use • Multiple user steps • Correct volume of blood and reagent • Convoluted workflow • Seamless delivery to test strip • High e
Slide 6: Atomo Platform Driving Adoption of Rapid Testing
ATOMO PLATFORM DRIVING ADOPTION OF RAPID TESTING EASY TO USE Simple to use products providing reliability and usability in decentralised settings For personal use only SPEED OF RESULTS Rapid results with a high degree of accuracy EASY TO OBTAIN & AFFORDABLE Accessibility online and increasingly thro
Slide 7: For personal use only
For personal use only
Slide 8: FY24 Profit & Loss
FY24 PROFIT & LOSS AUD FY24($m) FY23($m) (%) • Excluding COVID sales, revenue increased year-on-year (YoY) across core business by 90%. This was Revenue 4.09 2.54 61% predominantly made up of growth in HIV Test sales Cost of sales (2.48) (1.88) (Revenue of $3.2m) and increased OEM Cassettes sales 1.
Slide 9: FY24 Balance Sheet
FY24 BALANCE SHEET FY24 FY23 AUD ($m) ($m) • Atomo had a cash balance of $3.69 million as of For personal use only Cash and cash equivalents 3.69 6.47 30 June 2024, and the company remains debt Trade and other receivables 2.06 1.82 free Inventories 1.84 2.14 Property, plant and equipment 1.64 2.50 •
Slide 10: FY24 Cash Flow
FY24 CASH FLOW FY24 Cashflow Activities (#039;m) 12.00 0.76 • Cash receipts for the period totalled $6.8m 3.96 • ~$4m was received from product sales For personal use only 10.00 • $761k received from the R&D tax rebate (2.38) • ~$2m capital raised net of transaction 8.00 costs 6.47 6.00 • Cash payments
Slide 11: Supportive Financial Trends
SUPPORTIVE FINANCIAL TRENDS Well positioned for profitability with no need for significant CapEx to fund future revenue growth For personal use only Revenue, gross profit and gross profit margin all show OpEx continues to reduce materially, having come down material improvement ~30% over the past tw
Slide 12: Technology & Products
> - TECHNOLOGY _ OS =oF Sb “| ’ INIQ@ ooo: ¥ ee OO Le oe “* itlng J ee eee ene e ay parts. ‘ ee . _ PRODUCTS.
Slide 13: Blood Testing
45° IQ2 BLOOD TESTING 360° Atomo’s solutions offer improved performance and best in-class usability in point-of-care and self-testing Built-In Safety Lancet • Eliminates the risk of hazardous sharps injuries by locking For personal use only 70° the needle inside the device after use Accurate Blood C
Slide 14: Swab Testing
SWAB TESTING The Atomo Curie Platform utilises Atomo’s existing core IP and know-how to improve usability and performance of swab-based rapid tests 360° Compatible With Existing Swab-Based LF Strip Tests For personal use only IQ2 • Compatible with existing rapid test cassettes and swabs (nasal, naso
Slide 15: Digital Compatibility
DIGITAL COMPATIBILITY Atomo has developed solutions to deliver compatibility with POC reader and for at-home enabled smartphone-based testing, maximising ease of use, repeatability and accuracy of results Reader Compatibility • Atomo platforms are easily adapted for use in a range of POC For persona
Slide 16: Product Registrations
PRODUCT REGISTRATIONS Product Registrations – Atomo as Listed Manufacturer HIV Self Test | US$4bn (2026) [10] • TGA | Australia • WHO PQ | LMIC For personal use only • CE Mark | UK & Europe COVID-19 Antibody Test (Discontinued) • TGA | Australia Product Registrations – Atomo Partners Pregnancy Test
Slide 17: Commercialisation Strategy Growing and More Balanced Future
COMMERCIALISATION STRATEGY GROWING AND MORE BALANCED FUTURE Atomo has developed user-friendly platforms that support a broad range of diagnostic applications and technologies, REVENUE CHANNELS enabling the company to generate revenues from a number of commercial channels For personal use only Finish
Slide 18: For personal use only
For personal use only ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 19: Commercialisation Pipeline by Platform
COMMERCIALISATION PIPELINE BY PLATFORM Atomo’s lateral flow platforms have been developed to IN FEASIBILITY DEVELOPMENT COMMERCIALISED provide best-in-class usability and performance with blood and swab samples PASCAL Pascal – Commercialised and Supplied to Customers For personal use only • NG Biote
Slide 20: OEM Customers
OEM CUSTOMERS IN DEVELOPMENT NEW CUSTOMERS Lumos Diagnostics is a US company specialising in NG Biotech is a French diagnostics company focusing Atomo is working on several development For personal use only rapid, cost-effective point-of-care test solutions on the development and manufacture of nove
Slide 21: For personal use only
For personal use only ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 22: HIV Market Opportunities
HIV MARKET OPPORTUNITIES The HIV diagnostics market value is expected to grow to US$4bn by 2026 with a CAGR of 7.9% [13] HIV self-testing is expected to grow to US$531m by 2026 at a CAGR of For personal use only 30%. This very high growth rate is driven by convenience and privacy offered by self-tes
Slide 23: Atomo's HIV Business
ATOMO’S HIV BUSINESS IN AUSTRALIA & NZ GLOBAL HEALTH MARKETS UK and EUROPE DEVELOPMEN T Atomo HIV Self Test is the only WHO estimates HIV self-testing Increasing adoption of consumer approved test in the Australian markets in LMIC to be worth self-test through mainstream For personal use only market
Slide 24: Burnet Diagnostics Initiative
BURNET DIAGNOSTICS INITIATIVE Active Syphilis Substantial increase in syphilis cases around the world, with ~7m new cases of syphilis globally in 2020 according to WHO data. The Syphilis testing market is expected to be worth around US$1.4bn by 2026, growing at a CAGR of 5.6% [19] [20] For personal
Slide 25: Opportunities in Women's Health
OPPORTUNITIES IN WOMEN’S HEALTH Blood Pregnancy The pregnancy hormone hCG typically appears in blood earlier than urine, making blood ideal for early detection. Unlike urine pregnancy tests, blood tests are reliable any time of For personal use only day Atomo is currently working with NG Biotech to
Slide 26: Goals
GOALS Near-Term Progress go-to-market pathway to support entry into CLIA and OTC channels in US Complete strategic partnership with Burnet Diagnostics for commercialisation of further Pascal-based finished tests For personal use only Continue restructuring of Atomo’s operational footprint to achieve
Slide 27: Intellectual Property Portfolio
INTELLECTUAL PROPERTY PORTFOLIO Family 1: Diagnostic System PCT/AU2011/000315 Family 2: Sampling Assembly For personal use only PC/AU2011/001321 Family 3: Fluid Control in Integrated Testing Devices PCT/IB2014/066210 Family 4: Integrated Fluid Module and Test Device PCT/AU2016/051134 Family 5: Integ
Slide 28: Sources
SOURCES [1] BusinessWire, 2024, Global Point of Care Testing (POCT) Market Report 2023-2030: Continued Expansion of Point of Care Including Self Testing Fueling Growth - ResearchAndMarkets.com, BusinessWire, viewed 14 April 2024, <https://www.businesswire.com/news/home/20240115203040/en/Global-Point
Slide 29: Sources
SOURCES [15] PEPFAR, 2022, PEPFAR sets bold manufacturing targets for Africa, U.S. Department of State, viewed 30 April 2024, <https://www.state.gov/pepfar-sets-bold-manufacturing-targets-for-africa/>. [16] Shah, A., Mackay, N., Ratna, N., Chau, C., Okumu-Camerra, K., Kolawole, T., Martin, V., Humph